Hearing partially restored in deaf lab mice using novel therapy

A small molecule of a drug has been successfully used to treat an inherited form of hearing loss in laboratory mice. The study was conducted by researchers at the University of Iowa, Iowa City, and the National Institutes of Health’s National Institute on Deafness and Other Communication Disorders (NIDCD). It could mean that a new treatment option could be underway for people with this form of deafness. The results of the preliminary study were published in the latest issue of the journal Cell.

Top: Rows of healthy sensory hair cells in the mouse inner ear with green stereocilia arcs. Middle: In Rest mutant mice, hair cells are disorganized, and stereocilia barely visible. Bottom: In Rest mutant mice treated with HDAC inhibitors, organization and structure of hair cells is partially restored.Yoko Nakano, Carver College of Medicine, University of Iowa, Originally published in Cell
Top: Rows of healthy sensory hair cells in the mouse inner ear with green stereocilia arcs. Middle: In Rest mutant mice, hair cells are disorganized, and stereocilia barely visible. Bottom: In Rest mutant mice treated with HDAC inhibitors, organization and structure of hair cells is partially restored.Yoko Nakano, Carver College of Medicine, University of Iowa, Originally published in Cell

The team of researchers notes that using small molecule drug, this form of deafness called DFNA27, could be partially reversed. Thomas B. Friedman, chief of the Laboratory of Human Molecular Genetics at the NIDCD and a collaborating author of this study explained that this novel therapy could restore hearing at lower sound frequencies and save some of the “sensory hair cells” within the inner ear. He said that they were hopeful that more small molecules could be used in future to treat other forms of progressive deafness.

Friedman and Robert J. Morell from NIDCD, in their earlier study a few years back looked at the genetic basis in an inherited form of deafness. The family members and blood relations of the family called LMG2 carried a dominant gene which when passed on to the children caused progressive hearing loss among them. In the present form of hearing loss the team had found that there was a genetic mutation on chromosome four called DFNA27. There are quite a few genes at the place which when altered, could be affecting the hearing.

Botond Banfi and Yoko Nakano, University of Iowa, who led this current study found that mice with DFNA27 form of progressive deafness had a Rest gene (RE1 Silencing Transcription Factor). This gene is important because it regulates the sensory cells within the ear that are vital for hearing. In humans the counterpart of this Rest gene is found in the DFNA27 region. Once the location and function of this gene was better understood the teams from Iowa University and NIDCD teamed up to see what could modulate the gene and help improve the deafness.

To create the mice model of DFNA27 deafness, the team deleted a portion (called exon 4) of the Rest gene. This manipulation led to the death of the sensory hair cells within the mice inner ear rendering them deaf. Similar mutation changes in this region were found in the LMG2 family as well. Once this exon 4 region was inserted into the REST mRNA, explained Banfi, it switches off the REST protein. This in turn allows many of the genes to switch on and these latter genes help in survival of the sensory hair cells and allow the mice to listen better.

For this study the team thus used mice that had modified genetic code without the exon 4. They served as models for DFNA27 deafness. The REST protein normally suppresses the genes by a method called histone deacetylation. The team now used a small molecule of a drug that could block the process of histone deacetylation and thus turn off the REST. Switching off REST allowed a partial return of hearing they noted.

Andrew J. Griffith, scientific director of the NIDCD said that the results of this study show the value of understanding the “molecular mechanisms that underlie inherited forms of deafness.” “By following these genetic leads, we find novel and unexpected pathways that can, in cases such as this one, uncover unexpected potential treatment strategies in humans,” he said.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2019, June 19). Hearing partially restored in deaf lab mice using novel therapy. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20180628/Hearing-partially-restored-in-deaf-lab-mice-using-novel-therapy.aspx.

  • MLA

    Mandal, Ananya. "Hearing partially restored in deaf lab mice using novel therapy". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20180628/Hearing-partially-restored-in-deaf-lab-mice-using-novel-therapy.aspx>.

  • Chicago

    Mandal, Ananya. "Hearing partially restored in deaf lab mice using novel therapy". News-Medical. https://www.news-medical.net/news/20180628/Hearing-partially-restored-in-deaf-lab-mice-using-novel-therapy.aspx. (accessed October 11, 2024).

  • Harvard

    Mandal, Ananya. 2019. Hearing partially restored in deaf lab mice using novel therapy. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20180628/Hearing-partially-restored-in-deaf-lab-mice-using-novel-therapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Estrogen found to promote tumor growth in breast cancers without receptors